Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow
F Xiong, Q Wang, G Wu, W Liu, B Wang, Y Chen - Biomarker Research, 2022 - Springer
… Interferon-α2b (IFN-α2b) is a highly active cytokine that belongs to the interferon-α (IFN-α) …
This article reviews mechanistic studies and clinical trials on IFN-α2b. Potential regulators of …
This article reviews mechanistic studies and clinical trials on IFN-α2b. Potential regulators of …
The current state of treatment and future directions in cutaneous malignant melanoma
M Ernst, A Giubellino - Biomedicines, 2022 - mdpi.com
… (cisplatin, vinblastine or vindesine, and dacarbazine) and Dartmouth (carmustine, dacarbazine,
cisplatin, and tamoxifen) … a first-line therapy for stage II melanoma patients in 1998 based …
cisplatin, and tamoxifen) … a first-line therapy for stage II melanoma patients in 1998 based …
State of melanoma: an historic overview of a field in transition
L Karapetyan, JM Kirkwood - Hematology/Oncology Clinics, 2021 - hemonc.theclinics.com
Melanoma was first described in the literature in 1787 as a “soft and black tumor” by John
Hunter. The benefit of early surgical intervention and futility of interventions later in advanced …
Hunter. The benefit of early surgical intervention and futility of interventions later in advanced …
Chimeric antigen receptor T-cell therapy for melanoma
A Razavi, M Keshavarz-Fathi, J Pawelek… - Expert Review of …, 2021 - Taylor & Francis
… to dacarbazine alone were about half compared to combinations of cisplatin, vinblastine or
vindesine, and dacarbazine … ’ combining carmustine, cisplatin, and dacarbazine caused deep …
vindesine, and dacarbazine … ’ combining carmustine, cisplatin, and dacarbazine caused deep …
Targeting the IL-2 pathway for the treatment of mucosal melanoma
AC Mercurio, AB Maniar, AZ Wei… - Expert Opinion on …, 2022 - Taylor & Francis
… subcutaneous injections of IL-2 and interferon-α2b (IFN-α-2b), 3-… Dacarbazine has been
the only chemotherapy agent to … that temozolomide and cisplatin prolonged progression-free …
the only chemotherapy agent to … that temozolomide and cisplatin prolonged progression-free …
Investigation of differentially expressed genes that contribute to therapeutic effects of bevacizumab in BRAF mutant melanoma
N Coupe - 2020 - ora.ox.ac.uk
… outcomes were poor after resection of high-risk stage II and III … The management of high-risk
stage II and stage III disease … in the UK for patients with resected high-risk stage II and III …
stage II and stage III disease … in the UK for patients with resected high-risk stage II and III …
Incidenza di un nuovo melanoma cutaneo primario in pazienti con pregresso melanoma trattato con immunoterapia e terapia target: uno studio retrospettivo …
D OPPORTUNO - thesis.unipd.it
… Aim of the study: The aim of this study is to evaluate, in subjects previously treated with IT
or TT, the antitumor role of the two medical treatments on the development of new primary …
or TT, the antitumor role of the two medical treatments on the development of new primary …